Snapshot from Jul 07, 2026 at 01:18 UTC. For live data and tracking: View Live
Entities / Silevertinib
Other

Silevertinib

Tracked across 1 events · 6 articles · First seen Apr 21, 2026 · Last active Apr 21, 2026

Sentiment
60
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (1)
4 60
Tech
Black Diamond Therapeutics Silevertinib Phase 2 Data
Impact: Silevertinib is a key drug being developed by Black Diamond Therapeutics, with promising Phase 2 data for NSCLC and GBM being presented.
Apr 21, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Silevertinib live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.